News
-
-
COMMUNIQUÉ DE PRESSE
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany and 108% in September, leading to accelerated marketing efforts based on strong e-Rx metrics. Full-year 2024 guidance updated for increased marketing activity -
-
COMMUNIQUÉ DE PRESSE
Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax recrute premier patient pour Enhance-CD, essai clinique phase 2b obefazimod maladie Crohn. Etude 3 phases. Obefazimod, traitement prometteur -
COMMUNIQUÉ DE PRESSE
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax announces enrollment of first patient in Phase 2b trial of Obefazimod for Crohn's Disease, aiming for convenient, effective treatment option with fewer daily burdens -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September. Full-year guidance updated with strategic decision to accelerate marketing in Q4 based on convincing e-Rx metrics -
-
-
-
